ZA989615B - The use of TNF antagonists as drugs for treating septic 39disorders. - Google Patents

The use of TNF antagonists as drugs for treating septic 39disorders.

Info

Publication number
ZA989615B
ZA989615B ZA9809615A ZA989615A ZA989615B ZA 989615 B ZA989615 B ZA 989615B ZA 9809615 A ZA9809615 A ZA 9809615A ZA 989615 A ZA989615 A ZA 989615A ZA 989615 B ZA989615 B ZA 989615B
Authority
ZA
South Africa
Prior art keywords
drugs
tnf antagonists
treating septic
septic
treating
Prior art date
Application number
ZA9809615A
Inventor
Hartmut Kupper
Martin Kaul
Juergen Eiselstein
Lothar Daum
Joachim Kempeni
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of ZA989615B publication Critical patent/ZA989615B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA9809615A 1997-10-23 1998-10-22 The use of TNF antagonists as drugs for treating septic 39disorders. ZA989615B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19746868A DE19746868A1 (en) 1997-10-23 1997-10-23 Use of tumour necrosis factor antagonists

Publications (1)

Publication Number Publication Date
ZA989615B true ZA989615B (en) 2000-04-20

Family

ID=7846420

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9809615A ZA989615B (en) 1997-10-23 1998-10-22 The use of TNF antagonists as drugs for treating septic 39disorders.

Country Status (13)

Country Link
EP (1) EP1024831A2 (en)
JP (1) JP2001521009A (en)
KR (1) KR20010024549A (en)
CN (1) CN1163272C (en)
AU (1) AU756167B2 (en)
BR (1) BR9813114A (en)
CA (1) CA2306790A1 (en)
DE (1) DE19746868A1 (en)
HU (1) HUP0100105A3 (en)
IL (1) IL135083A0 (en)
NO (1) NO20001894D0 (en)
WO (1) WO1999021582A2 (en)
ZA (1) ZA989615B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (en) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Method of treatment of pathological syndrome and medicinal agent
UA76640C2 (en) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Method for correcting pathological immune responses and homeopathic medicinal agent
UA76639C2 (en) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Homeopathic medication and method for treating erectile dysfunctions
RU2309732C1 (en) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Pressed solid oral formulation of medicinal preparation and method for preparing solid oral formulation of medicinal preparation
KR101901465B1 (en) 2010-07-15 2018-09-21 올레그 일리치 엡쉬테인 Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
SG187038A1 (en) 2010-07-15 2013-02-28 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
EP2415461B1 (en) * 2010-07-24 2012-10-31 Roche Diagnostics GmbH Stabilization of interleukin 6 in serum based solutions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626572B2 (en) * 1988-07-18 1992-08-06 Chiron Corporation Monoclonal antibodies reactive with cachectin
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above

Also Published As

Publication number Publication date
BR9813114A (en) 2000-08-15
EP1024831A2 (en) 2000-08-09
CN1163272C (en) 2004-08-25
NO20001894L (en) 2000-04-12
JP2001521009A (en) 2001-11-06
KR20010024549A (en) 2001-03-26
HUP0100105A2 (en) 2001-05-28
AU756167B2 (en) 2003-01-09
HUP0100105A3 (en) 2003-08-28
DE19746868A1 (en) 1999-04-29
CN1277556A (en) 2000-12-20
WO1999021582A2 (en) 1999-05-06
WO1999021582A3 (en) 1999-07-15
IL135083A0 (en) 2001-05-20
NO20001894D0 (en) 2000-04-12
CA2306790A1 (en) 1999-05-06
AU1228499A (en) 1999-05-17

Similar Documents

Publication Publication Date Title
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
GB2321719B (en) Liquid treatment
ZA99454B (en) Novel dosage form.
AU3642795A (en) Endothelin receptor antagonists for the treatment of emesis
HUP0003851A3 (en) Pharmaceutical composition for the treatment or prevention of glomerulopathy
IL133136A0 (en) Use of leptin antagonists for the treatment of diabetes
ZA973209B (en) Therapeutic compounds.
AU3167095A (en) Pth or pthrp antagonists
ZA989615B (en) The use of TNF antagonists as drugs for treating septic 39disorders.
ZA978640B (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis.
ZA974811B (en) Novel therapeutic compounds.
ZA976350B (en) Treatment of liquid.
PL338781A1 (en) Dosage form
GB9811525D0 (en) Sewage treatment
GB9928195D0 (en) Over-flow saftey system
PT1011678E (en) Use of mecamylamine for the treatment of nicotine-responsive neuropsychiatric disorders
GB2331514B (en) Effluent treatment
ZA9711116B (en) The treatment of materials.
ZA9811824B (en) Drinkable pharmaceutical composition.
ZA981275B (en) Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions.
ZA9811598B (en) A substance or composition for the treatment of cancer.
ZA983775B (en) Process for the preparation of halogenated hydrocarbons.
ZA9810329B (en) "Water treatment means".
ZA994277B (en) Arrangement for the use of waste water.
SI1200158T1 (en) Mixture for the treatment of waste materials